WuXi Biologics is trading at HK$42.40, down 12.90%, amid weak sector and risk-off sentiment.
- No confirmed company-specific announcement explaining the November 6 decline was found; recent coverage of its Fresenius biosimilar agreement predates the move.
- Biotech ETF XBI fell 5.19% during the session amid a broader technology and growth-stock sell-off; available reporting does not establish a direct WuXi-specific cause.